Payment overview · 2025
General Payments
$502.50
27 reported records · 15 companies
Healthcare provider profile · identity verified
Dorotea M Gabel, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · SPARTANBURG, SC · NPI 1336110410
Verified facts
What the public records show
CMS Open Payments records show Dorotea M Gabel, M.D. received $502.50 in general payments during 2025 across 27 reported records.
Amgen Inc. accounted for 11.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Mounjaro.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 138 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Mounjaro by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 101 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $58.36 | 11.6% | 4 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $55.19 | 11.0% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $49.32 | 9.8% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $48.66 | 9.7% | 2 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $42.87 | 8.5% | 2 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$41.79 | 8.3% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $38.51 | 7.7% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $30.18 | 6.0% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $26.80 | 5.3% | 1 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $24.66 | 4.9% | 1 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $21.52 | 4.3% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.17 | 3.6% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $16.86 | 3.4% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $15.09 | 3.0% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.52 | 2.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $502.50 | 27 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $55.19 | 3 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $48.66 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $43.01 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $43.01 | 3 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $42.87 | 2 | 2025 |
Source payment records
|
|||||
| INTELLIS ADAPTIVESTIM Normalized: intellis adaptivestim |
Device | Medtronic, Inc. | $41.79 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $34.08 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $34.08 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $30.18 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $30.18 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $26.80 | 1 | 2025 |
Source payment records
|
|||||
| EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Normalized: edwards sapien 3 transcatheter heart valve thv |
Device | Edwards Lifesciences Corporation | $24.66 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $24.11 | 1 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $21.52 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $18.17 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $16.86 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $15.35 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $15.24 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $15.24 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $15.24 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $15.09 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.52 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $14.40 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 101 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
89 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
138 | 28 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
43 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
101 | 31 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
11 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 572 | 139 |
| Amlodipine Besylate | Amlodipine Besylate | 559 | 166 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 451 | 140 |
| Pantoprazole Sodium | Pantoprazole Sodium | 428 | 130 |
| Atorvastatin Calcium | Atorvastatin Calcium | 418 | 115 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 381 | 64 |
| Metoprolol Succinate | Metoprolol Succinate | 376 | 112 |
| Gabapentin | Gabapentin | 321 | 102 |
| Furosemide | Furosemide | 313 | 101 |
| Lisinopril | Lisinopril | 294 | 83 |
| Omeprazole | Omeprazole | 284 | 84 |
| Clonazepam | Clonazepam | 274 | 49 |
| Metoprolol Tartrate | Metoprolol Tartrate | 268 | 73 |
| Pravastatin Sodium | Pravastatin Sodium | 268 | 79 |
| Losartan Potassium | Losartan Potassium | 254 | 82 |
| Lorazepam | Lorazepam | 250 | 58 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 227 | 90 |
| Alprazolam | Alprazolam | 225 | 39 |
| Metformin Hcl | Metformin Hcl | 211 | 55 |
| Duloxetine Hcl | Duloxetine Hcl | 205 | 63 |
| Tramadol Hcl | Tramadol Hcl | 193 | 47 |
| Montelukast Sodium | Montelukast Sodium | 186 | 55 |
| Memantine Hcl | Memantine Hcl | 183 | 60 |
| Carvedilol | Carvedilol | 173 | 52 |
| Famotidine | Famotidine | 172 | 63 |
| Potassium Chloride | Potassium Chloride | 169 | 60 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 166 | 62 |
| Hydrochlorothiazide | Hydrochlorothiazide | 164 | 48 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 159 | 128 |
| Ezetimibe | Ezetimibe | 156 | 44 |
| Glipizide | Glipizide | 141 | 37 |
| Farxiga | Dapagliflozin Propanediol | 138 | 28 |
| Fluticasone Propionate | Fluticasone Propionate | 137 | 49 |
| Clopidogrel | Clopidogrel Bisulfate | 134 | 40 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 132 | 45 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 131 | 24 |
| Diazepam | Diazepam | 130 | 25 |
| Sertraline Hcl | Sertraline Hcl | 127 | 39 |
| Tizanidine Hcl | Tizanidine Hcl | 123 | 39 |
| Trazodone Hcl | Trazodone Hcl | 120 | 39 |
| Spironolactone | Spironolactone | 119 | 32 |
| Simvastatin | Simvastatin | 118 | 32 |
| Zolpidem Tartrate | Zolpidem Tartrate | 117 | 20 |
| Meclizine Hcl | Meclizine Hcl | 107 | 50 |
| Temazepam | Temazepam | 103 | 23 |
| Eliquis | Apixaban | 101 | 31 |
| Atenolol | Atenolol | 98 | 15 |
| Donepezil Hcl | Donepezil Hcl | 98 | 38 |
| Fluoxetine Hcl | Fluoxetine Hcl | 94 | 23 |
| Methylprednisolone | Methylprednisolone | 91 | 75 |
| Methocarbamol | Methocarbamol | 89 | 23 |
| Myrbetriq | Mirabegron | 89 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 88 | 26 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 84 | 26 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 83 | 23 |
| Bupropion Xl | Bupropion Hcl | 79 | 25 |
| Clonidine Hcl | Clonidine Hcl | 78 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 77 | 28 |
| Allopurinol | Allopurinol | 74 | 22 |
| Pregabalin | Pregabalin | 69 | 21 |
| Azithromycin | Azithromycin | 68 | 58 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 67 | 16 |
| Tamsulosin Hcl | Tamsulosin Hcl | 65 | 21 |
| Mupirocin | Mupirocin | 64 | 28 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 63 | 19 |
| Metformin Hcl Er | Metformin Hcl | 63 | 21 |
| Promethazine Hcl | Promethazine Hcl | 63 | 21 |
| Mirtazapine | Mirtazapine | 62 | 24 |
| Fluconazole | Fluconazole | 59 | 43 |
| Ropinirole Hcl | Ropinirole Hcl | 59 | 18 |
| Amoxicillin | Amoxicillin | 57 | 50 |
| Fenofibrate | Fenofibrate,micronized | 56 | 14 |
| Januvia | Sitagliptin Phosphate | 53 | 11 |
| Buspirone Hcl | Buspirone Hcl | 51 | 17 |
| Doxazosin Mesylate | Doxazosin Mesylate | 51 | 16 |
| Lovastatin | Lovastatin | 51 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 50 | 13 |
| Verapamil Er | Verapamil Hcl | 50 | 13 |
| Nystatin | Nystatin | 49 | 22 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 48 | 19 |
| Colestipol Hcl | Colestipol Hcl | 46 | 12 |
| Propranolol Hcl Er | Propranolol Hcl | 46 | suppressed |
| Baclofen | Baclofen | 45 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 44 | 24 |
| Solifenacin Succinate | Solifenacin Succinate | 43 | 16 |
| Symbicort | Budesonide/Formoterol Fumarate | 43 | 16 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 42 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 42 | 34 |
| Benazepril Hcl | Benazepril Hcl | 41 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 40 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 40 | 35 |
| Citalopram Hbr | Citalopram Hydrobromide | 40 | 12 |
| Celecoxib | Celecoxib | 39 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 39 | suppressed |
| Meloxicam | Meloxicam | 38 | 13 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 38 | suppressed |
| Lansoprazole | Lansoprazole | 36 | 12 |
| Prednisone | Prednisone | 35 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 34 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 34 | 11 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 33 | suppressed |
| Synthroid | Levothyroxine Sodium | 33 | suppressed |
| Glimepiride | Glimepiride | 32 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 31 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 31 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 31 | 11 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 30 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 30 | suppressed |
| Glipizide Er | Glipizide | 30 | 11 |
| Topiramate | Topiramate | 30 | suppressed |
| Valsartan | Valsartan | 30 | suppressed |
| Estradiol | Estradiol | 29 | suppressed |
| Nifedipine Er | Nifedipine | 29 | suppressed |
| Ozempic | Semaglutide | 29 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 29 | 14 |
| Nitroglycerin | Nitroglycerin | 28 | 14 |
| Warfarin Sodium | Warfarin Sodium | 28 | suppressed |
| Levetiracetam | Levetiracetam | 26 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 24 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 22 | suppressed |
| Xarelto | Rivaroxaban | 22 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 21 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 21 | suppressed |
| Jardiance | Empagliflozin | 21 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 21 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 20 | 13 |
| Propranolol Hcl | Propranolol Hcl | 19 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 19 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Ondansetron Odt | Ondansetron | 18 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 18 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 18 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 17 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 17 | 17 |
| Bumetanide | Bumetanide | 16 | suppressed |
| Lactulose | Lactulose | 16 | suppressed |
| Mounjaro | Tirzepatide | 16 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 16 | suppressed |
| Olanzapine | Olanzapine | 16 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 15 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 15 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 15 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 15 | suppressed |
| Colchicine | Colchicine | 14 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Finasteride | Finasteride | 14 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 14 | suppressed |
| Ibuprofen | Ibuprofen | 14 | suppressed |
| Entresto | Sacubitril/Valsartan | 13 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 13 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 13 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 13 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Mirabegron Er | Mirabegron | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 11 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Nystop | Nystatin | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $502.50 · 27 records | Amgen Inc. | ABRYSVO, AIRSUPRA, BREZTRI, COMIRNATY, Cologuard Collection Kit, Dexcom G6 Transmitter, EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV), ELIQUIS, EVENITY, INTELLIS ADAPTIVESTIM, LEQVIO, MOUNJARO, NURTEC ODT, OTEZLA, PREVNAR 20, REPATHA, REXULTI, TZIELD, Tymlos, VOQUEZNA, Veozah, Wegovy, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error